The prognostic value of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio in the treatment response and survival of patients with peripheral T-cell lymphoma

References

• Yang QP, Zhang WY, Yu JB, et al. Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. Diagn Pathol. 2011;6(1):77.
   PubMedGoogle Scholar
• Sun J, Yang Q, Lu Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012;138(3):429–434.
   PubMed Web of Science ®Google Scholar
• Shi Y. Current status and progress of lymphoma management in China. Int J Hematol. 2018;107(4):405–412.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin's lymphoma: an update. Lancet Oncol. 2004;5(6):341–353.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumors of haematopoietic and lymphold tissues. Lyon, France: IARC; 2016.
   Google Scholar
• Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. JCO. 2013;31(16):1970–1976.
   PubMed Web of Science ®Google Scholar
• International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–2479.
   PubMed Web of Science ®Google Scholar
• Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389–400.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444.
   PubMed Web of Science ®Google Scholar
• Carbone A, Tripodo C, Carlo-Stella C, et al. The role of inflammation in lymphoma. Adv Exp Med Biol. 2014;816:315–333.
   PubMed Web of Science ®Google Scholar
• Deng Q, He B, Liu X, et al. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med. 2015;13(1):66.
   PubMedGoogle Scholar
• Krenn-Pilko S, Langsenlehner U, Thurner EM, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer. 2014;110(10):2524–2530.
   PubMed Web of Science ®Google Scholar
• Koh CH, Bhoo-Pathy N, Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1):150–158.
   PubMed Web of Science ®Google Scholar
• Wade RG, Robinson AV, Lo MCI, et al. Baseline neutrophil-lymphocyte and platelet-lymphocyte ratios as biomarkers of survival in cutaneous melanoma: a multicenter cohort study. Ann Surg Oncol. 2018;25(11):3341–3349.
   PubMed Web of Science ®Google Scholar
• Scilla KA, Bentzen SM, Lam VK, et al. Neutrophil-lymphocyte ratio is a prognostic marker in patients with locally advanced (stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist. 2017;22(6):737–742.
   PubMed Web of Science ®Google Scholar
• Dolan RD, McSorley ST, Park JH, et al. The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores. Br J Cancer. 2018;119(1):40–51.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ristow K, Habermann T, et al. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol. 2010;85(11):896–899.
   PubMed Web of Science ®Google Scholar
• Marcheselli R, Bari A, Tadmor T, et al. Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol. 2017;35(4):561–566.
   PubMed Web of Science ®Google Scholar
• Reddy JP, Hernandez M, Gunther JR, et al. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol. 2018;180(4):545–549.
   PubMed Web of Science ®Google Scholar
• Kelkitli E, Atay H, Cilingir F, et al. Predicting survival for multiple myeloma patients using baseline neutrophil/lymphocyte ratio. Ann Hematol. 2014;93(5):841–846.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, et al. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–545.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nat Immunol. 2008;9(7):705–712.
   PubMed Web of Science ®Google Scholar
• Uribe-Querol E, Rosales C. Neutrophils in cancer: Two sides of the same coin. J Immunol Res. 2015;2015:1.
   Web of Science ®Google Scholar
• Manfroi B, Moreaux J, Righini C, et al. Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients. Blood Cancer J. 2018;8(7):66.
   PubMedGoogle Scholar
• Schalk E, Zeremski V, Fischer T. Impact of lymphopenia on prognosis of patients with primary central nervous system lymphoma. Eur J Cancer. 2017;75:280–283.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Rsitow K, Inwards DJ, et al. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia. 2010;24(7):1343–1349.
   PubMed Web of Science ®Google Scholar
• Mitrovic Z, Perry AM, Suzumiya J, et al. The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project. Am J Hematol. 2012;87(8):790–794.
   PubMed Web of Science ®Google Scholar
• Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. Blood. 2015;126(5):582–588.
   PubMed Web of Science ®Google Scholar
• Olsson AK, Cedervall J. The pro-inflammatory role of platelets in cancer. Platelets. 2018;29(6):569–573.
   PubMed Web of Science ®Google Scholar
• Bernardo A, Ball C, Nolasco L, et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost. 2005;3(3):562–570.
   PubMed Web of Science ®Google Scholar
• Del Conde I, Crúz MA, Zhang H, et al. Platelet activation leads to activation and propagation of the complement system. J Exp Med. 2005;201(6):871–879.
   PubMed Web of Science ®Google Scholar
• Eriksson O, Mohlin C, Nilsson B, et al. The human platelet as an innate immune cell: interactions between activated platelets and the complement system. Front Immunol. 2019;10:1590.
   PubMed Web of Science ®Google Scholar
• Montalbán C, Abraira V, Arcaini L, et al. Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol. 2012;159(2):164–171.
   PubMed Web of Science ®Google Scholar
• Wang KF, Chang BY, Chen XQ, et al. A prognostic model based on pretreatment platelet lymphocyte ratio for stage IE/IIE upper aerodigestive tract extranodal NK/T cell lymphoma, nasal type. Med Oncol. 2014;31(12):318.
   PubMed Web of Science ®Google Scholar
• Choi M, Lee JO, Jung J, et al. Prognostic value of platelet count in patients with peripheral T cell lymphoma. Acta Haematol. 2019;141(3):176–186.
   PubMed Web of Science ®Google Scholar
• Feng X, Li L, Wu J, et al. Complete blood count score model integrating reduced lymphocyte-monocyte ratio, elevated neutrophil-lymphocyte ratio, and elevated platelet-lymphocyte ratio predicts inferior clinical outcomes in adult T-lymphoblastic lymphoma. Oncologist. 2019;24(1):e1123–e1131.
   PubMedGoogle Scholar
• Beltran BE, Castro D, De La Cruz-Vargas JA, et al. The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. Br J Haematol. 2019;184(4):650–653.
   PubMed Web of Science ®Google Scholar
• Beltran BE, Aguilar C, Quiñones P, et al. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2016;57(1):58–62.
   PubMed Web of Science ®Google Scholar